Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer

Lung Cancer

Volumn 76, Issue 2, 2012, Pages 171-176

  Jeon, Hyo Sung ^a   Lee, Soo Young ^b   Lee, Eun Jin ^a   Yun, Seong Cheol ^c   Cha, Eun Jung ^c   Choi, Eugene ^c   Na, Moon Jun ^c   Park, Jae Yong ^d   Kang, Jaeku ^b   Son, Ji Woong ^b,c  

^a Kyungpook National University School of Medicine   (South Korea)

^b Konyang University   (South Korea)

^c Konyang University College of Medicine   (South Korea)

^d Kyungpook National University Hospital   (South Korea)

Author keywords

HDAC1; MicroRNA; Non small cell lung cancer

Indexed keywords

HISTONE DEACETYLASE; MICRORNA;

3' UNTRANSLATED REGION; ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GROWTH DISORDER; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

3' UNTRANSLATED REGIONS; ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOWN-REGULATION; DRUG SYNERGISM; GROWTH INHIBITORS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROTEIN BINDING; TUMOR STEM CELL ASSAY;

EID: 84859434875     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.10.012     Document Type: Article

References (34)

1. Cress W.D., Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000, 184:1-16.
2. Thiagalingam S.A.M., Cheng K.-H., Lee H.J., Mineva N., Thiagalingam A., Ponte J.F. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003, 983:84-100.
3. Langer R., Mutze K., Becker K., Feith M., Ott K., Höfler H., et al. Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study. J Clin Pathol 2010, 63:994-998.
4. Nakagawa M., Oda Y., Eguchi T., Aishima S., Yao T., Hosoi F., et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007, 18:769-774.
5. Krusche C., Wulfing P., Kersting C., Vloet A., Bocker W., Kiesel L., et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005, 90:15-23.
6. Fritzsche F., Weichert W., Roske A., Gekeler V., Beckers T., Stephan C., et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 2008, 8:381.
7. Weichert W., Roske A., Gekeler V., Beckers T., Ebert M., Pross M., et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008, 9:139-148.
8. Weichert W., Roske A., Niesporek S., Noske A., Buckendahl A., Dietel M., et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008, 14:1669-1677.
9. Sasaki H., Moriyama S., Nakashima Y., Kobayashi Y., Kiriyama M., Fukai I., et al. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 2004, 46:171-178.
10. Minamiya Y., Ono T., Saito H., Takahashi N., Ito M., Mitsui M., et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2011, 74:300-304.
11. Noonan E.J., Place R.F., Pookot D., Basak S., Whitson J.M., Hirata H., et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009, 28:1714-1724.
12. Marks P.A., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1:194-202.
13. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6:38-51.
14. Ropero S., Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007, 1:19-25.
15. Weichert W., Röske A., Gekeler V., Beckers T., Ebert M.P.A., Pross M., et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008, 9:139-148.
16. Weichert W., Roske A., Gekeler V., Beckers T., Stephan C., Jung K., et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008, 98:604-610.
17. Halkidou K., Gaughan L., Cook S., Leung H.Y., Neal D.E., Robson C.N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004, 59:177-189.
18. Park S.Y., Jun J.A., Jeong K.J., Heo H.J., Sohn J.S., Lee H.Y., et al. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncol Rep 2011, 25:1677-1681.
19. Wang S., Yan-Neale Y., Fischer D., Zeremski M., Cai R., Zhu J., et al. Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line. Oncogene 2003, 22:6204-6213.
20. Yao Y.-L., Yang W.-M. The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity. J Biol Chem 2003, 278:42560-42568.
21. Mazumdar A., Wang R.-A., Mishra S.K., Adam L., Bagheri-Yarmand R., Mandal M., et al. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 2001, 3:30-37.
22. Osada H., Takahashi T. let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer Sci 2011, 102:9-17.
23. Marcet B., Chevalier B., Luxardi G., Coraux C., Zaragosi L.-E., Cibois M., et al. Control of vertebrate multiciliogenesis by miR-449 through direct repression of the Delta/Notch pathway. Nat Cell Biol 2011, 13:693-699.
24. Kim M.S., Kwon H.J., Lee Y.M., Baek J.H., Jang J.E., Lee S.W., et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001, 7:437-443.
25. Deroanne C.F., Bonjean K., Servotte S., Devy L., Colige A., Clausse N., et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002, 21:427-436.
26. Neuzil J., Swettenham E., Gellert N. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochem Biophys Res Commun 2004, 314:186-191.
27. Sun Y., Chin Y.E., Weisiger E., Malter C., Tawara I., Toubai T., et al. Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J Immunol 2009, 182:5899-5903.
28. Traynor A.M., Dubey S., Eickhoff J.C., Kolesar J.M., Schell K., Huie M.S., et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network Phase II Study. J Thorac Oncol 2009, 4:522-526.
29. Ramalingam S.S., Maitland M.L., Frankel P., Argiris A.E., Koczywas M., Gitlitz B., et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:56-62.
30. Ma W.W., Adjei A.A. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009, 59:111-137.
31. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
32. Morales J.C., Ruiz-Magaña M.J., Carranza D., Ortiz-Ferrón G., Ruiz-Ruiz C. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis. Cancer Lett 2010, 297:91-100.
33. Khan N., Jeffers M., Kumar S., Hackett C., Boldog F., Khramtsov N., et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008, 409:581-589.
34. Kwon S.H., Ahn S.H., Kim Y.K., Bae G.-U., Yoon J.W., Hong S., et al. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 2002, 277:2073-2080.